Zapalenie brzegów powiek – wszechstronne spojrzenie na powszechne schorzenie Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
sie 31, 2020
Słowa kluczowe:
zapalenie brzegów powiek, nużeniec, dysfunkcja gruczołów Meiboma
##plugins.themes.bootstrap3.article.main##
Abstrakt
Zapalenie brzegów powiek to rozpowszechniona na całym świecie, częsta, przewlekła choroba zapalna aparatu ochronnego oczu, której szczegółowa epidemiologia jest trudna do ustalenia. Również rola poszczególnych czynników etiologicznych, takich jak kolonizacja nużeńcem, pozostaje niedookreślona. Rozpoznanie opiera się na wszechstronnym badaniu przedmiotowym w połączeniu z dokładnym badaniem okulistycznym, uzupełnionym o ewentualne badania dodatkowe. Terapia jest długotrwała i zwykle nie prowadzi do pełnego wyleczenia, wymaga od pacjentów cierpliwości i systematycznego zaangażowania. Stale poszerzany wachlarz terapeutyczny pozostaje poza refundacją w ramach publicznej opieki zdrowotnej większości krajów.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
1.
Karaszewski M, Misiuk-Hojło M, Przeździecka-Dołyk J, Gnus J. Zapalenie brzegów powiek – wszechstronne spojrzenie na powszechne schorzenie. Ophthatherapy [Internet]. 31 sierpień 2020 [cytowane 23 listopad 2024];7(3):192-0. Dostępne na: https://journalsmededu.pl/index.php/ophthatherapy/article/view/1054
Numer
Dział
Terapie zachowawcze
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Bowling B. Eyelids. In: Kanski’s Clinical Ophthalmology. 2016.
2. Soh Qin R, Tong Hak Tien L. Healthcare delivery in meibomian gland dysfunction and blepharitis. Ocul Surf. 2019; 17(2): 176-8.
3. The Definition and Classification of Dry Eye Disease: Report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007). Ocul Surf. 2007; 5(2): 75-92.
4. Arita R, Itoh K, Inoue K et al. Noncontact Infrared Meibography to Document Age-Related Changes of the Meibomian Glands in a Normal Population. Ophthalmology. 2008; 115(5): 911-5.
5. Lemp MA, Nichols KK. Blepharitis in the United States 2009: A survey-based perspective on prevalence and treatment. Ocul Surf. 2009; 7(2 suppl): S1.
6. Schaumberg DA, Nichols JJ, Papas EB et al. The international workshop on meibomian gland dysfunction: Report of the subcommittee on the epidemiology of, and associated risk factors for, MGD. Investig Ophthalmol Vis Sci. 2011; 52(4): 1994-2005.
7. Stanek S. Meibomian gland status comparison between active duty personnel and U.S. veterans. Mil Med. 2000; 165(8): 591-3.
8. Amescua G, Akpek EK, Farid M et al. Blepharitis Preferred Practice Pattern®. Ophthalmology. 2018; 126: P56-93.
9. Bowman RW, Dougherty JM, McCulley JP. Chronic blepharitis and dry eyes. Int Ophthalmol Clin. 1987; 27(1): 27-35.
10. McCulley JP, Dougherty JM, Deneau DG. Classification of chronic blepharitis. Ophthalmology. 1982; 89(10): 1173-80.
11. Baum J. Clinical manifestations of dry eye states. Trans Ophthalmol Soc U K. 1985; 104 (Pt 4): 415-23.
12. Bozkurt B, Irkeç MT, Atakan N et al. Lacrimal function and ocular complications in patients treated with systemic isotretinoin. Eur J Ophthalmol. 2002; 12(3): 173-6.
13. Arici MK, Sümer Z, Toker MI et al. The prevalence of Demodex folliculorum in blepharitis patients and the normal population. Ophthalmic Epidemiol. 2005; 12(4): 287-90.
14. Gao YY, Di Pascuale MA, Li W et al. High prevalence of Demodex in eyelashes with cylindrical dandruff. Investig Ophthalmol Vis Sci. 2005; 46(9): 3089-94.
15. Koo H, Kim TH, Kim KW et al. Ocular surface discomfort and demodex: Effect of tea tree oil eyelid scrub in demodex blepharitis. J Korean Med Sci. 2012; 27(12): 1574-9.
16. Deeks ED. Ivermectin: A Review in Rosacea. Am J Clin Dermatol. 2015; 16(5): 447-52.
17. Nicholls SG, Oakley CL, Tan A et al. Demodex species in human ocular disease: new clinicopathological aspects. Int Ophthalmol. 2017; 37(1): 303-12.
18. Plewig G, Kligman AM. ACNE and ROSACEA. Berlin, Heidelberg: Springer Berlin Heidelberg; 2000.
19. Kheirkhah A, Blanco G, Casas V et al. Fluorescein dye improves microscopic evaluation and counting of Demodex in blepharitis with cylindrical dandruff. Cornea. 2007; 26(6): 697-700.
20. Conjunctivitis PPP – 2018 – American Academy of Ophthalmology. https://www.aao.org/preferred-practice-pattern/conjunctivitis-ppp-2018.
21. Jones SM, Weinstein JM, Cumberland P et al. Visual Outcome and Corneal Changes in Children with Chronic Blepharokeratoconjunctivitis. Ophthalmology. 2007; 114(12): 2271-80.
22. Hammersmith KM, Cohen EJ, Blake TD et al. Blepharokeratoconjunctivitis in children. Arch Ophthalmol. 2005; 123, 1667-70.
23. Donaldson KE, Karp CL, Dunbar MT. Evaluation and treatment of children with ocular rosacea. Cornea. 2007; 26(1): 42-6.
24. Çetinkaya A, Akova YA. Pediatric Ocular Acne Rosacea: Long-Term Treatment With Systemic Antibiotics. Am J Ophthalmol. 2006; 142(5): 816-21.
25. Viswalingam M, Rauz S, Morlet N et al. Blepharokeratoconjunctivitis in children: diagnosis and treatment. Br J Ophthalmol. 2005; 89(4): 400-3.
26. Pflugfelder SC, Tseng SCG, Sanabria O et al. Evaluation of subjective assessments and objective diagnostic tests for diagnosing tearfilm disorders known to cause ocular irritation. Cornea. 1998; 17: 38-56.
27. Grabska-Liberek I, Mrukwa-Kominek E, Szaflik J et al. Wytyczne Polskiego Towarzystwa Okulistycznego dotyczące diagnostyki i leczenie Zespołu Suchego Oka. 2018: 9-10, 12. https://www.pto.com.pl/storage/guidelines/35/714c0222f3d8edfaf6e4b2ab89e4e34a.pdf.
28. Acharya N, Pineda R, Uy HS et al. Discoid Lupus Erythematosus Masquerading as Chronic Blepharoconjunctivitis. Ophthalmology. 2005; 112(5): e19-23.
29. Diaz-Valle D, Benitez Del Castillo JM, Fernandez Aceñero MJ et al. Bilateral lid margin ulcers as the initial manifestation of crohn disease. Am J Ophthalmol. 2004; 138(2): 292-4.
30. Key JE. A comparative study of eyelid cleaning regimens in chronic blepharitis. CLAO J. 1996; 22(3): 209-12.
31. Lindsley K, Matsumura S, Hatef E et al. Interventions for chronic blepharitis. Cochrane Database Syst Rev. 2012; (5): CD005556.
32. Foulks GN, Borchman D, Yappert M et al. Topical azithromycin therapy for meibomian gland dysfunction: Clinical response and lipid alterations. Cornea. 2010; 29(7): 781-8.
33. Haque RM, Torkildsen GL, Brubaker K et al. Multicenter open-label study evaluating the efficacy of azithromycin ophthalmic solution 1% on the signs and symptoms of subjects with blepharitis. Cornea. 2010; 29(8): 871-7.
34. Torkildsen GL, Cockrum P, Meier E et al. Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3/0.05 compared to azithromycin ophthalmic solution 1 in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis. Curr Med Res Opin. 2011; 27(1): 171-8.
35. Ray WA, Murray KT, Hall K et al. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012; 366(20): 1881-90.
36. Nogueira Filho PA, Hazarbassanov RM, Grisolia ABD et al. The efficacy of oral ivermectin for the treatment of chronic blepharitis in patients tested positive for Demodex spp. Br J Ophthalmol. 2011; 95: 893-5.
37. Asbell PA, Maguire G, Pistilli M et al. n−3 Fatty acid supplementation for the treatment of dry eye disease. N Engl J Med. 2018; 378(18): 1681-90.
38. Macsai MS. The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (An AOS thesis). Trans Am Ophthalmol Soc. 2008; 106: 336-56.
39. Jones L, Downie LE, Korb D et al. TFOS DEWS II Management and Therapy Report. Ocul Surf. 2017; 15(3): 575-628.
40. Perry HD, Doshi-Carnevale S, Donnenfeld ED et al. Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction. Cornea. 2006; 25(2): 171-5.
41. Dobrowolski D, Gil L, Grabska-Liberek I et al. Zapobieganie i leczenie ciężkiego zapalenia rogówki w przebiegu zespołu suchego oka. Wytyczne PTO, PTR, PTHiT. 2019. http://pto.com.pl/wytyczne.
42. Margo CE, Mulla ZD. Malignant tumors of the eyelid: A population-based study of non-basal cell and non-squamous cell malignant neoplasms. Arch Ophthalmol. 1998; 116(2): 195-8.
43. Blackie CA, Coleman CA, Holland EJ. The sustained effect (12 months) of a single-dose vectored thermal pulsation procedure for meibomian gland dysfunction and evaporative dry eye. Clin Ophthalmol. 2016; 10: 1385-96.
44. Greiner J V. Long-term (12-month) improvement in meibomian gland function and reduced dry eye symptoms with a single thermal pulsation treatment. Clin Exp Ophthalmol. 2013; 41(6): 524-30.
45. Murphy O, O’Dwyer V, Lloyd-McKernan A. The efficacy of tea tree face wash, 1, 2-Octanediol and microblepharoexfoliation in treating Demodex folliculorum blepharitis. Contact Lens Anterior Eye. 2018; 41(1): 77-82.
46. van Zuuren EJ, Fedorowicz Z, Carter B et al. Interventions for rosacea. Vol. 2017, Cochrane Database Syst Rev. John Wiley and Sons Ltd; 2015: 83.
47. Palumbo R. The bright side of patient empowerment. In: SpringerBriefs in Public Health. 2017.
2. Soh Qin R, Tong Hak Tien L. Healthcare delivery in meibomian gland dysfunction and blepharitis. Ocul Surf. 2019; 17(2): 176-8.
3. The Definition and Classification of Dry Eye Disease: Report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007). Ocul Surf. 2007; 5(2): 75-92.
4. Arita R, Itoh K, Inoue K et al. Noncontact Infrared Meibography to Document Age-Related Changes of the Meibomian Glands in a Normal Population. Ophthalmology. 2008; 115(5): 911-5.
5. Lemp MA, Nichols KK. Blepharitis in the United States 2009: A survey-based perspective on prevalence and treatment. Ocul Surf. 2009; 7(2 suppl): S1.
6. Schaumberg DA, Nichols JJ, Papas EB et al. The international workshop on meibomian gland dysfunction: Report of the subcommittee on the epidemiology of, and associated risk factors for, MGD. Investig Ophthalmol Vis Sci. 2011; 52(4): 1994-2005.
7. Stanek S. Meibomian gland status comparison between active duty personnel and U.S. veterans. Mil Med. 2000; 165(8): 591-3.
8. Amescua G, Akpek EK, Farid M et al. Blepharitis Preferred Practice Pattern®. Ophthalmology. 2018; 126: P56-93.
9. Bowman RW, Dougherty JM, McCulley JP. Chronic blepharitis and dry eyes. Int Ophthalmol Clin. 1987; 27(1): 27-35.
10. McCulley JP, Dougherty JM, Deneau DG. Classification of chronic blepharitis. Ophthalmology. 1982; 89(10): 1173-80.
11. Baum J. Clinical manifestations of dry eye states. Trans Ophthalmol Soc U K. 1985; 104 (Pt 4): 415-23.
12. Bozkurt B, Irkeç MT, Atakan N et al. Lacrimal function and ocular complications in patients treated with systemic isotretinoin. Eur J Ophthalmol. 2002; 12(3): 173-6.
13. Arici MK, Sümer Z, Toker MI et al. The prevalence of Demodex folliculorum in blepharitis patients and the normal population. Ophthalmic Epidemiol. 2005; 12(4): 287-90.
14. Gao YY, Di Pascuale MA, Li W et al. High prevalence of Demodex in eyelashes with cylindrical dandruff. Investig Ophthalmol Vis Sci. 2005; 46(9): 3089-94.
15. Koo H, Kim TH, Kim KW et al. Ocular surface discomfort and demodex: Effect of tea tree oil eyelid scrub in demodex blepharitis. J Korean Med Sci. 2012; 27(12): 1574-9.
16. Deeks ED. Ivermectin: A Review in Rosacea. Am J Clin Dermatol. 2015; 16(5): 447-52.
17. Nicholls SG, Oakley CL, Tan A et al. Demodex species in human ocular disease: new clinicopathological aspects. Int Ophthalmol. 2017; 37(1): 303-12.
18. Plewig G, Kligman AM. ACNE and ROSACEA. Berlin, Heidelberg: Springer Berlin Heidelberg; 2000.
19. Kheirkhah A, Blanco G, Casas V et al. Fluorescein dye improves microscopic evaluation and counting of Demodex in blepharitis with cylindrical dandruff. Cornea. 2007; 26(6): 697-700.
20. Conjunctivitis PPP – 2018 – American Academy of Ophthalmology. https://www.aao.org/preferred-practice-pattern/conjunctivitis-ppp-2018.
21. Jones SM, Weinstein JM, Cumberland P et al. Visual Outcome and Corneal Changes in Children with Chronic Blepharokeratoconjunctivitis. Ophthalmology. 2007; 114(12): 2271-80.
22. Hammersmith KM, Cohen EJ, Blake TD et al. Blepharokeratoconjunctivitis in children. Arch Ophthalmol. 2005; 123, 1667-70.
23. Donaldson KE, Karp CL, Dunbar MT. Evaluation and treatment of children with ocular rosacea. Cornea. 2007; 26(1): 42-6.
24. Çetinkaya A, Akova YA. Pediatric Ocular Acne Rosacea: Long-Term Treatment With Systemic Antibiotics. Am J Ophthalmol. 2006; 142(5): 816-21.
25. Viswalingam M, Rauz S, Morlet N et al. Blepharokeratoconjunctivitis in children: diagnosis and treatment. Br J Ophthalmol. 2005; 89(4): 400-3.
26. Pflugfelder SC, Tseng SCG, Sanabria O et al. Evaluation of subjective assessments and objective diagnostic tests for diagnosing tearfilm disorders known to cause ocular irritation. Cornea. 1998; 17: 38-56.
27. Grabska-Liberek I, Mrukwa-Kominek E, Szaflik J et al. Wytyczne Polskiego Towarzystwa Okulistycznego dotyczące diagnostyki i leczenie Zespołu Suchego Oka. 2018: 9-10, 12. https://www.pto.com.pl/storage/guidelines/35/714c0222f3d8edfaf6e4b2ab89e4e34a.pdf.
28. Acharya N, Pineda R, Uy HS et al. Discoid Lupus Erythematosus Masquerading as Chronic Blepharoconjunctivitis. Ophthalmology. 2005; 112(5): e19-23.
29. Diaz-Valle D, Benitez Del Castillo JM, Fernandez Aceñero MJ et al. Bilateral lid margin ulcers as the initial manifestation of crohn disease. Am J Ophthalmol. 2004; 138(2): 292-4.
30. Key JE. A comparative study of eyelid cleaning regimens in chronic blepharitis. CLAO J. 1996; 22(3): 209-12.
31. Lindsley K, Matsumura S, Hatef E et al. Interventions for chronic blepharitis. Cochrane Database Syst Rev. 2012; (5): CD005556.
32. Foulks GN, Borchman D, Yappert M et al. Topical azithromycin therapy for meibomian gland dysfunction: Clinical response and lipid alterations. Cornea. 2010; 29(7): 781-8.
33. Haque RM, Torkildsen GL, Brubaker K et al. Multicenter open-label study evaluating the efficacy of azithromycin ophthalmic solution 1% on the signs and symptoms of subjects with blepharitis. Cornea. 2010; 29(8): 871-7.
34. Torkildsen GL, Cockrum P, Meier E et al. Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3/0.05 compared to azithromycin ophthalmic solution 1 in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis. Curr Med Res Opin. 2011; 27(1): 171-8.
35. Ray WA, Murray KT, Hall K et al. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012; 366(20): 1881-90.
36. Nogueira Filho PA, Hazarbassanov RM, Grisolia ABD et al. The efficacy of oral ivermectin for the treatment of chronic blepharitis in patients tested positive for Demodex spp. Br J Ophthalmol. 2011; 95: 893-5.
37. Asbell PA, Maguire G, Pistilli M et al. n−3 Fatty acid supplementation for the treatment of dry eye disease. N Engl J Med. 2018; 378(18): 1681-90.
38. Macsai MS. The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (An AOS thesis). Trans Am Ophthalmol Soc. 2008; 106: 336-56.
39. Jones L, Downie LE, Korb D et al. TFOS DEWS II Management and Therapy Report. Ocul Surf. 2017; 15(3): 575-628.
40. Perry HD, Doshi-Carnevale S, Donnenfeld ED et al. Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction. Cornea. 2006; 25(2): 171-5.
41. Dobrowolski D, Gil L, Grabska-Liberek I et al. Zapobieganie i leczenie ciężkiego zapalenia rogówki w przebiegu zespołu suchego oka. Wytyczne PTO, PTR, PTHiT. 2019. http://pto.com.pl/wytyczne.
42. Margo CE, Mulla ZD. Malignant tumors of the eyelid: A population-based study of non-basal cell and non-squamous cell malignant neoplasms. Arch Ophthalmol. 1998; 116(2): 195-8.
43. Blackie CA, Coleman CA, Holland EJ. The sustained effect (12 months) of a single-dose vectored thermal pulsation procedure for meibomian gland dysfunction and evaporative dry eye. Clin Ophthalmol. 2016; 10: 1385-96.
44. Greiner J V. Long-term (12-month) improvement in meibomian gland function and reduced dry eye symptoms with a single thermal pulsation treatment. Clin Exp Ophthalmol. 2013; 41(6): 524-30.
45. Murphy O, O’Dwyer V, Lloyd-McKernan A. The efficacy of tea tree face wash, 1, 2-Octanediol and microblepharoexfoliation in treating Demodex folliculorum blepharitis. Contact Lens Anterior Eye. 2018; 41(1): 77-82.
46. van Zuuren EJ, Fedorowicz Z, Carter B et al. Interventions for rosacea. Vol. 2017, Cochrane Database Syst Rev. John Wiley and Sons Ltd; 2015: 83.
47. Palumbo R. The bright side of patient empowerment. In: SpringerBriefs in Public Health. 2017.